Clinic Degenerative Disc Disease Events 
OrthoSpineNews
MAY 13, 2025
No serious adverse events (SAEs) were reported, and there was no dose (40X10 6 cells) limiting toxicity at 26-104 weeks. About the BRTX-100 Phase 2 Trial in cLDD BRTX-100, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow, is the Companys lead clinical candidate.
OrthoSpineNews
MARCH 3, 2025
patient in its Investigational Device Exemption (IDE) clinical trial for the PerQdisc Nucleus Replacement Device (NRD). This event marks the beginning of SST’s U.S.-based based trial to evaluate its PerQdisc system for patients suffering from degenerative disc disease (DDD).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
OrthoSpineNews
JUNE 17, 2025
“This share repurchase program reflects our confidence in the strength of our clinical development pipeline and the future outlook of our business,” said Lance Alstodt, Chief Executive Officer of BioRestorative. MELVILLE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. We have also obtained U.S.
OrthoSpineNews
JUNE 23, 2025
Food and Drug Administration (FDA) premarket approval (PMA) of PearlMatrix P-15 Peptide Enhanced Bone Graft as a Class III drug-device combination product for use in single-level transforaminal lumbar interbody fusion (TLIF) surgery in adult patients with degenerative disc disease (DDD). 3 The ASPIRE trial included 33 U.S.
OrthoSpineNews
JULY 8, 2025
This transaction places Paradigm Spine with a team of people who are well-equipped to complete the remaining clinical and regulatory work and take these fantastic technologies to the next level. million cash deposits may be paid to Xtant by Companion Spine in the event it requires extra time to obtain financing. ” Anthony G.
Any Spine
SEPTEMBER 30, 2024
Clinical trials have shown the effectiveness of chiropractic spinal adjustments in reducing pain, including issues in the shoulder area, often providing a complementary option alongside other treatments like acupuncture.
OrthoSpineNews
MARCH 10, 2025
This prospective, multi-center, multi-specialty clinical trial is the first of its kind to evaluate the safety and efficacy of lumbar interlaminar fusion devices, marking a significant milestone in the advancement of spinal care. CARLSBAD, Calif.,
Expert insights. Personalized for you.
Let's personalize your content